• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Finding Comfort in Teddy Bears Throughout My Experience With CLL

by MM360 Staff | May 15, 2025 | Uncategorized

Source: CureToday articles As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself. Read More

Efti Plus Keytruda With Chemo Shows High Response in NSCLC Subset

by MM360 Staff | May 15, 2025 | Uncategorized

Source: CureToday articles Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data. Read More

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

by MM360 Staff | May 15, 2025 | Uncategorized

Source: CureToday articles The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC. Read More

Lumakras Plus Vectibix Shows Potential in KRAS G12C Colorectal Cancer

by MM360 Staff | May 15, 2025 | Uncategorized

Source: CureToday articles Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though not statistically significant. Read More

Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

by MM360 Staff | May 15, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses. Read...

Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

by MM360 Staff | May 15, 2025 | Uncategorized

Source: CureToday articles Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant Read More
« Older Entries
Next Entries »

Recent Content

  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT